Sustained Virologic Suppression Reduces HIV-1 DNA Proviral Levels and HIV Antibodies in Perinatally HIV-Infected

Trevon Fuller1,2, Tara Kerin3, Ruth Cortado3

  • 1Institute of the Environment & Sustainability, University of California Los Angeles, Los Angeles, CA 90095, USA.

Viruses
|November 11, 2022
PubMed

Insights

Long-term viral suppression in children with perinatal HIV infection is linked to reduced HIV reservoirs and lower HIV antibody levels. Early combination antiretroviral therapy (cART) helps achieve this, impacting HIV DNA and RNA viral loads.

Area of Science:

  • Pediatric Infectious Diseases
  • Virology
  • Immunology

Background:

  • Perinatally HIV-infected children on combination antiretroviral therapy (cART) may develop low proviral reservoirs.
  • The impact of cART timing and duration on HIV DNA levels and antibody responses in these children is not fully understood.

Purpose of the Study:

  • To investigate the long-term proviral HIV DNA reservoir size and HIV antibody levels in perinatally HIV-infected children after initiating cART.
  • To assess the correlation between the timing of cART initiation, viral load suppression, and reservoir size.

Main Methods:

  • Prospective study of 37 perinatally HIV-infected children initiating stable cART before 6 months or after 6 months of age.
  • Measurement of plasma HIV RNA viral load (VL), proviral HIV DNA using droplet-digital PCR (ddPCR), and HIV antibody by Western Blot (WB) at school age (6-11 years).

Main Results:

  • HIV DNA levels at school age did not significantly differ based on cART initiation timing.
  • Children with negative/indeterminate Western Blot (WB) results had significantly lower HIV DNA levels (p=0.0256).
  • Children with >50% undetectable HIV RNA VL since cART initiation showed a trend towards lower median HIV DNA VL (p=0.07).

Conclusions:

  • Long-term viral suppression in perinatally HIV-infected children is associated with decreased HIV antibody levels.
  • Reduced HIV proviral DNA reservoirs are linked to sustained viral suppression and potentially negative/indeterminate HIV antibody status.